Literature DB >> 9308253

IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.

P L Bergsagel1, E Nardini, L Brents, M Chesi, W M Kuehl.   

Abstract

Dysregulation of c-myc by translocation to the switch regions of the IgH locus occurs in most murine plasmacytomas. Translocations involving 14q32 have been reported in 20-40% of abnormal karyotypes from human multiple myeloma (MM), and involve a variety of loci. Using cytogenetics, FISH and a Southern blot assay, we analyzed 21 MM cells lines and one plasma cell leukemia and identified evidence of a 14q32 translocation in 20/22 samples. The partner loci involved are 11q13 in 6 (associated with cyclin D1 expression), 4p16 in 6 (associated with FGFR3 expression), unidentified in 3 and 1p13, 6, 8q24, 12q24, 16q23, and 21q22 once each. We conclude that conventional karyotypes underestimate the frequency of 14q32 translocations in MM, where they appear to be a nearly universal event. The translocations most frequently involve IgH switch regions, and include two recurrent partner loci (11q13 and 4p16) and a promiscuous array of other partner loci. Although c-myc appears to be cis-dysregulated frequently in MM, it is only rarely translocated to the IgH locus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308253     DOI: 10.1007/978-3-642-60801-8_30

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  9 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

2.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

Review 4.  [Molecular pathology of plasma cell neoplasms].

Authors:  F Fend
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma.

Authors:  S Gharagozloo; R A Sharifian; R A Mageed; F Shokri
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

6.  Bcl-1 rearrangement and cyclin D1 protein expression in multiple myeloma precursor cells.

Authors:  X Liu; Z Tang; P Zou
Journal:  J Tongji Med Univ       Date:  2000

7.  MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Authors:  Jose L R Brito; Brian Walker; Matthew Jenner; Nicholas J Dickens; Nicola J M Brown; Fiona M Ross; Athanasia Avramidou; Julie A E Irving; David Gonzalez; Faith E Davies; Gareth J Morgan
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

Review 8.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

9.  Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?

Authors:  Gilberto Gastelum; Mysore Veena; Kylee Lyons; Christopher Lamb; Nicole Jacobs; Alexandra Yamada; Alisher Baibussinov; Martin Sarafyan; Rebeka Shamis; Jeffry Kraut; Patrick Frost
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.